Asia/Oceania
Vivace Therapeutics Begins Phase I Trial of TEAD Inhibitor
The trial will include patients with mesothelioma and solid tumors that have progressed on standard treatments and harbor an NF2 mutation.
FDA Accepts IND for Jacobio Pharmaceuticals' KRAS G12C Inhibitor
The firm, which plans to begin enrolling patients in clinical trials of JAB-21822 later this year, is also developing SHP2 inhibitors for combination therapy.
In Brief This Week:Â Johnson & Johnson, AstraZeneca, Geneseeq, Osborn Cancer Care
News items for the week of April 26, 2021.Â
Burning Rock Biotech, Abbisko Therapeutics Ink CDx Partnership for ABSK091
Burning Rock will use its sequencing platform to identify urothelial carcinoma patients with FGFR alterations, supporting development of Abbisko's drug.
NuProbe, AcornMed to Develop Cancer Minimal Residual Disease Detection Products
The companies aim to validate NuProbe's blocker displacement amplification technology for MRD monitoring in genitourinary and hematologic cancer patients.
Mar 16, 2021
Acepodia Raises $47M in Series B Financing
Feb 23, 2021